1. Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic;Huang;Curr Opin Investig Drugs,2002
2. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR;Neshat;Proc Natl Acad Sci USA,2001
3. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer;Yu;Endocr Relat Cancer,2001
4. CCI-779 a rapamycin analog with antitumor activity a phase I study utilizing a weekly schedule;Raymond;Proc Am Soc Clin Oncol,2000
5. A randomized double-blind phase II study of intravenous CCI-779 administrated weekly to patients with advanced renal cell carcinoma;Atkins;Proc Am Soc Clin Oncol,2002